Seeking Alpha

Merck gets FDA nod for allergy drug

  • An FDA advisory committee panel unanimously agrees the available data support the efficacy and safety of Merck's (MRK) GRASTEK for treating pollen allergy in those aged 5 and up. The panel did recommend post-approval studies for those aged 5-11, citing some side effects.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector